Himension Capital (Singapore) Pte. Ltd. Editas Medicine, Inc. Transaction History

Himension Capital (Singapore) Pte. Ltd.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$14.08 - $27.63 $3.69 Million - $7.24 Million	-262,198 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$26.55 - $40.57 $897,390 - $1.37 Million	33,800 Added 14.8%	262,198 $6.96 Million
Q3 2021 Nov 10, 2021	BUY	$39.27 - $72.94 $3.36 Million - $6.24 Million	85,602 Added 59.95%	228,398 $9.38 Million
Q2 2021 Aug 03, 2021	BUY	$31.29 - $56.64 $3.68 Million - $6.66 Million	117,556 Added 465.75%	142,796 $8.09 Million
Q1 2021 May 07, 2021	BUY	$39.71 - $90.58 $1 Million - $2.29 Million	25,240 New	25,240 $1.06 Million

243

69.3M

564K

428K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $312M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Himension Capital (Singapore) Pte. Ltd., based on Form 13F filings with the SEC.

Stay updated on Himension Capital (Singapore) Pte. Ltd. with notifications on news.